ATAI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AtaiBeckley Inc (ATAI) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company's strong pipeline in treatment-resistant depression, recent breakthrough therapy designation, insider and hedge fund buying trends, and favorable analyst ratings with high price targets make it a compelling opportunity despite short-term price volatility.
The MACD is slightly positive and contracting, indicating potential stabilization. RSI is neutral at 48.969, and moving averages are converging, suggesting no clear trend. Key support is at $3.453, with resistance at $4.127. The stock is slightly below its pivot point of $3.79.
Breakthrough Therapy Designation for BPL-003 in treatment-resistant depression.
Cash runway secured until early
Insider buying increased by 653.97% and hedge fund buying increased by 121.20%.
Analysts have high price targets ($11-$
and positive sentiment on the company's pipeline.
Strategic exploration of a $2 billion deal for BPL-003.
Recent price decline of 5.91% in the regular market session.
High implied volatility (416.41%) indicates potential price swings.
Historical financial losses, with net income at -$544.81 million in Q4 2025.
In Q4 2025, revenue was flat YoY at $1.066 million. Net income improved significantly YoY by 1298.46%, but remains negative at -$544.81 million. EPS improved by 620.83% to -1.73. Gross margin remained steady at 100%.
Analysts from Guggenheim and JonesResearch have initiated coverage with Buy ratings and price targets of $11 and $16, respectively, citing a strong pipeline, differentiated assets, and potential for rapid adoption in treatment-resistant depression.
